Physician profile
Michael Charles Romig
NPI 1982917233
$15,952.56
in general payments reported to CMS, 2019-2025
31 companies · $4,647 in 2025
The $4,647 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $613 · 2021: $736 · 2022: $2,052 · 2023: $3,723 · 2024: $3,275 · 2025: $4,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,606 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,750 · Travel and Lodging: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,605.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,750.00 |
| Travel and Lodging | $1,288.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5,982.18 | 2019-2025 | Lifevest |
| Medtronic, INC. | $3,226.24 | 2021-2025 | Omniasecure Mri Surescan, Linq II, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $1,394.18 | 2019-2025 | Aveir, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $1,093.30 | 2019-2025 | |
| Abiomed | $630.49 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $540.74 | 2022-2025 | Eliquis, Camzyos |
| Philips North America LLC | $451.95 | 2020-2023 | |
| Boston Scientific Corporation | $406.96 | 2022-2025 | Watchman, Bodyguardian, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $336.75 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.96 | 2021-2023 | Jardiance |
| Pfizer INC. | $225.57 | 2021-2025 | |
| Biotronik INC. | $144.57 | 2021-2025 | Biomonitor |
| Medtronic Vascular, INC. | $133.82 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $132.48 | 2019-2024 | Lokelma, Farxiga |
| United Therapeutics Corporation | $125.03 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.74 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Cvrx, INC. | $114.17 | 2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $99.18 | 2019-2023 | |
| Atricure, INC. | $74.90 | 2019 | |
| Amgen INC. | $72.65 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $55.69 | 2019-2023 | Uptravi, Opsumit |
| Elutia, INC. | $54.32 | 2019-2022 | |
| Baxter Healthcare | $49.62 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Ethicon US, LLC | $34.82 | 2024 | Ethicon, Vistaseal |
| Lexicon Pharmaceuticals, INC. | $33.47 | 2023 | Inpefa |
| Inspire Medical Systems, INC. | $29.78 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $28.02 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $26.45 | 2025 | |
| Esperion Therapeutics, INC. | $17.50 | 2024 | Nexletol |
| Hospira, INC. | $15.95 | 2019 | |
| Terumo Medical Corporation | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Romig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.